Terms: = Thyroid cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
15 results:
1. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.
Ren Z; Yang K; Zhu L; Yin D; Zhou Y
Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
[TBL] [Abstract] [Full Text] [Related]
2. Vascular endothelial growth factor inhibitors promote antitumor responses via tumor microenvironment immunosuppression in advanced colorectal cancer.
Hamada Y; Tanoue K; Kita Y; Tanabe K; Hokonohara K; Wada M; Hozaka Y; Oi H; Nakayama C; Higashi M; Arigami T; Mori S; Ohtsuka T
Scand J Gastroenterol; 2023; 58(9):1009-1020. PubMed ID: 36987919
[TBL] [Abstract] [Full Text] [Related]
3. Spontaneous Murine Model of Anaplastic thyroid cancer.
Yan H; Ma Y; Zhou X; He Y; Liu Y; Caulin C; Wang L; Xu H; Luo H
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36804915
[TBL] [Abstract] [Full Text] [Related]
4. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of thyroid cancer.
Bertol BC; Bales ES; Calhoun JD; Mayberry A; Ledezma ML; Sams SB; Orlicky DJ; Donadi EA; Haugen BR; French JD
Thyroid; 2022 Feb; 32(2):153-163. PubMed ID: 34641722
[No Abstract] [Full Text] [Related]
5. p53 Activation Effect in the Balance of T Regulatory and Effector Cell Subsets in Patients With thyroid cancer and Autoimmunity.
Arena A; Stigliano A; Belcastro E; Giorda E; Rosado MM; Grossi A; Assenza MR; Moretti F; Fierabracci A
Front Immunol; 2021; 12():728381. PubMed ID: 34539667
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer.
Li W; Xu M; Li Y; Huang Z; Zhou J; Zhao Q; Le K; Dong F; Wan C; Yi P
J Transl Med; 2020 Feb; 18(1):92. PubMed ID: 32070368
[TBL] [Abstract] [Full Text] [Related]
7. Notch signaling pathway regulates CD4
Yang L; Zhao KL; Qin L; Ji DX; Zhang B; Zheng PF; Qin YM
Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988066
[TBL] [Abstract] [Full Text] [Related]
8. Shenmai injection improves the postoperative immune function of papillary thyroid carcinoma patients by inhibiting differentiation into Treg cells via miR-103/GPER1 axis.
Fang T; Li J; Wu X
Drug Dev Res; 2018 Nov; 79(7):324-331. PubMed ID: 30267584
[TBL] [Abstract] [Full Text] [Related]
9. MicroRNA-125b Interacts with foxp3 to Induce Autophagy in thyroid cancer.
Wang S; Wu J; Ren J; Vlantis AC; Li MY; Liu SYW; Ng EKW; Chan ABW; Luo DC; Liu Z; Guo W; Xue L; Ng SK; van Hasselt CA; Tong MCF; Chen GG
Mol Ther; 2018 Sep; 26(9):2295-2303. PubMed ID: 30005868
[TBL] [Abstract] [Full Text] [Related]
10. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic thyroid cancer.
Bastman JJ; Serracino HS; Zhu Y; Koenig MR; Mateescu V; Sams SB; Davies KD; Raeburn CD; McIntyre RC; Haugen BR; French JD
J Clin Endocrinol Metab; 2016 Jul; 101(7):2863-73. PubMed ID: 27045886
[TBL] [Abstract] [Full Text] [Related]
11. Role of estrogen receptor in breast cancer cell gene expression.
Zheng Y; Shao X; Huang Y; Shi L; Chen B; Wang X; Yang H; Chen Z; Zhang X
Mol Med Rep; 2016 May; 13(5):4046-50. PubMed ID: 27035558
[TBL] [Abstract] [Full Text] [Related]
12. Phase Ia Study of foxp3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in cancer Patients.
Kurose K; Ohue Y; Wada H; Iida S; Ishida T; Kojima T; Doi T; Suzuki S; Isobe M; Funakoshi T; Kakimi K; Nishikawa H; Udono H; Oka M; Ueda R; Nakayama E
Clin Cancer Res; 2015 Oct; 21(19):4327-36. PubMed ID: 26429981
[TBL] [Abstract] [Full Text] [Related]
13. foxp3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway.
Ma S; Wang Q; Ma X; Wu L; Guo F; Ji H; Liu F; Zhao Y; Qin G
Tumour Biol; 2016 Jan; 37(1):989-98. PubMed ID: 26264613
[TBL] [Abstract] [Full Text] [Related]
14. MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.
Angell TE; Lechner MG; Jang JK; LoPresti JS; Epstein AL
Clin Cancer Res; 2014 Dec; 20(23):6034-44. PubMed ID: 25294906
[TBL] [Abstract] [Full Text] [Related]
15. foxp3 expression in papillary thyroid carcinoma: a possible resistance biomarker to iodine 131 treatment.
Ugolini C; Elisei R; Proietti A; Pelliccioni S; Lupi C; Borrelli N; Viola D; Leocata P; Vitti P; Miccoli P; Toniolo A; Basolo F
Thyroid; 2014 Feb; 24(2):339-46. PubMed ID: 23915122
[TBL] [Abstract] [Full Text] [Related]
